M | O | C Cancer Care Achieves Milestone with First Successful CAR-T Therapy
Successfully discharged its first patient who underwent CAR-T cell therapy for Relapsed Refractory Diffuse Large B-Cell Lymphoma, a type of hematological cancer
This accomplishment places M | O | C among the pioneering community cancer care institutions in India to offer this advanced & life-saving therapy
This achievement was made possible with the help of ImmunoACT, whose expertise in CAR-T cell manufacturing enabled the delivery of this transformative therapy
M | O | C Cancer Care has achieved a groundbreaking milestone in oncology by successfully discharging its first patient who underwent CAR-T cell therapy for Relapsed Refractory Diffuse Large B-Cell Lymphoma (DLBCL), a type of hematological cancer. This accomplishment places M | O | C among the pioneering community cancer care institutions in India to offer this advanced and life-saving therapy.
The patient, a 60-year-old resident of Thane, was admitted after battling relapsed and refractory lymphoma for over three years. Previous treatments, including immunotherapy, had been unsuccessful. Following CAR-T therapy, the patient experienced no complications and was successfully discharged.
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary advancement in cancer treatment. It involves genetically modifying a patient's own T-cells to precisely target and destroy cancer cells. By harnessing the immune system's power, CAR-T therapy provides new hope to patients with aggressive and previously untreatable blood cancers.
This achievement was made possible with the help of ImmunoACT, whose expertise in CAR-T cell manufacturing enabled the delivery of this transformative therapy.
This milestone underscores M | O | C’s commitment to pioneering advanced therapies and delivering world-class cancer care. “CAR-T therapy is particularly significant for patients with relapsed and refractory lymphomas, who have limited options after the failure of conventional treatments,” said Dr. Suraj Chiraniya.
Dr. Suraj Chiraniya & Dr. Ashray Kole, Hemato-Oncologists & BMT Specialists at M | O | C, added, “This breakthrough marks the beginning of a new era in oncology care, bringing renewed hope to countless patients and families battling complex blood cancers.”
Key Highlights of the CAR-T Success Story
Patient Details: 60-year-old male from Thane, Mumbai
Condition: Relapsed Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Treatment Timeline: Admitted on November 5, 2024; discharged on November 24, 2024
Background: Failed three prior treatment regimens, including immunotherapy
Outcome: Achieved successful remission post-CAR-T therapy
This achievement solidifies Mumbai’s position as a hub for advanced oncology care. M | O | C is proud to lead the way in bringing innovative cancer treatments to private healthcare settings, offering new hope to patients and their families.